A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition: Hepatocellular Carcinoma (HCC) Interventions: Drug: Durvalumab; Drug: Bevacizumab; Procedure: Transarterial Radioembolization (TARE) Sponsor: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Avastin | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Research | Study